Bronstein, Gewirtz & Grossman, LLC Announces Investigation of NovoCure Limited (NVCR)

Published June 7, 2023

NEW YORK, NY / ACCESSWIRE / June 7, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ:NVCR). Investors who purchased NovoCure securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:

Bronstein, Gewirtz and Grossman, LLC, Wednesday, June 7, 2023, Press release picture

The investigation concerns whether NovoCure and certain of its officers and/or directors have violated federal securities laws.

On June 6, 2023, NovoCure issued a press release announcing "positive results" from the Phase 3 LUNAR clinical trial evaluating the use of its Tumor Treating Fields ("TTFields") therapy together with standard therapies for the treatment of non-small cell lung cancer.Despite reporting that patients receiving TTFields combined with standard therapies achieved median overall survival ("OS") of 13.2 months, compared to 9.9 months for patients treated only with standard therapies, analysts noted that the therapy was tested in patients who worsened following chemotherapy, which is no longer the standard of care in lung cancer, and that most patients first receive immune checkpoint inhibitors ("ICIs").Although the Company stated that there was a "profound OS benefit" with a subgroup of patients who received ICIs, only a few patients (66) were treated with ICIs.On this news, NovoCure's ordinary share price fell $35.51 per share, or 43.04%, to close at $47.00 per share on June 6, 2023.

If you are aware of any facts relating to this investigation or purchased NovoCure shares, you can assist this investigation by visiting the firm's site: You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 |

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on


News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.